Adverum Biotechnologies (ADVM) Reports First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration
Tweet Send to a Friend
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the first patient was dosed in the OPTIC phase 1 trial evaluating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
